Picture of Verici Dx logo

VRCI Verici Dx News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

REG - Verici Dx PLC - Board Changes

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251006:nRSF1661Ca&default-theme=true

RNS Number : 1661C  Verici Dx PLC  06 October 2025

Verici Dx plc

("Verici Dx" or the "Company")

 

Board Changes

 

Aubrey Powell appointed as Non-executive Director

 

Verici Dx plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces the appointment to the Board of Aubrey Powell, as
Non-executive Director, with immediate effect. At the same time, Dr Erik Lium,
Non-executive Director since August 2020 and representative of Mount Sinai on
the Board, will step down from the Board with immediate effect.

 

Aubrey has over 30 years' experience in supporting and advising growth
companies, 26 of which have been spent in investment banking and corporate
finance. He trained at Salomon Brothers (now Citi) for two years before
transitioning to small and mid-cap roles at Panmure Gordon where he spent 12
years (including buyside investment and portfolio company support, as well as
early-stage public companies at Durlacher prior to Panmure Gordon's reverse
takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer
Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified
Executive and advising Main Market companies, as Sponsor, on their
obligations.

 

Aubrey has extensive experience in deal execution in equity capital markets
and M&A, for public companies as well as private, and has focused
predominantly on Healthcare and Life Sciences, TMT and other
technology-enabled businesses, over the course of his career. He brings a
blend of skills from corporate finance to deal-making, as well as a strong
track record of effectively guiding clients through reporting cycles, which
supports his proposed role as a member of the Audit Committee, as well as
advising on their wider regulatory and investor obligations including
corporate governance.

 

Previous experience also includes strategic consultancy covering growth and
investment decision-making, as well as corporate communications, and working
in biotech research for ICI Pharmaceuticals.

 

 

Aubrey Powell, Non-executive Director of Verici Dx plc

 

Julian Baines, MBE, Non-executive Chairman of Verici Dx, said:

"On behalf of the Board, I would like to thank Erik for his contribution to
the Company over the last five years, supporting us through our AIM IPO and
the transition to a business building commercial scale."

 

"I am delighted to welcome Aubrey to the Board, and know from first-hand
experience just how important his knowledge and expertise can be for AIM
quoted growth companies in the healthcare space. Aubrey knows the Verici Dx
business well, having previously acted as the lead member of the advisory team
at our NOMAD, Singer Capital Markets, and we know that his guidance and
challenge, as we enter a pivotal stage in the Company's growth, will be
invaluable."

 

Additional Disclosures Required under the AIM Rules for Companies

In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey
Richard Powell (aged 54) currently holds the following directorship:

 

·    Aubrey Powell Consulting (APC) Limited

 

Previous directorships or partnerships of which the director has been a
director or partner over the last five years:

 

·    Apus Sequestration LLP

·    Maia Green LLP

 

Mr Powell holds no shares in the Company.

 

There is no further information to be disclosed in respect of the above
appointment pursuant to Rule 17 or paragraph (g) of Schedule 2 of the AIM
Rules for Companies.

 

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated adviser and Joint Broker)                   Tel: +44 (0)20 7496 3000
 Phil Davies / Sam Butcher

 Oberon Capital (Joint Broker)                 Tel: +44 (0)20 3179 0500
 Mike Seabrook / Jessica Cave

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
 Alice Woodings / Paul McManus                 Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADGBDGUGGDGUU

Recent news on Verici Dx

See all news